<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

AACR 2023 Poster 497

HX301, a First-in-class ARK5i, Demonstrates Antitumor Activity in Preclinical HCC Models with High ARK5/Myc Expression

Zhihua Jiao1, Jessie Wang1, Hang Ke2, Faming Zhang2, and Henry Li2

1Crown Bioscience, Inc., 16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, USA
2Hanx Biopharmaceuticals, Ltd., Oceanside, California, US

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with few treatment options. Current drug therapies are often ineffective and toxic, and HCC has a poor prognosis. ARK5, a novel AMP-activated protein kinase family member 5, is overexpressed in many malignancies, including HCC, and is associated with poor prognosis and drug resistance. HX301 is a clinical stage first-in-class inhibitor of ARK5 and other kinase activities. In this study, HX301's antitumor activity was evaluated in HCC overexpressing both ARK5 and c-myc.

Download this Poster to Discover:

  • The limitations of current drug therapies for HCC

  • The role of ARK5 in HCC and its association with poor prognosis and drug resistance

  • The potential of HX301 as a first-in-class ARK5 inhibitor for the treatment of advanced HCC with high expression of c-myc.

Download the Poster Now!

Download Now

Your privacy is important to us.
We'll never share your information.